Nivolumab
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hepatocellular Carcinoma
Conditions
Hepatocellular Carcinoma, Liver Cancer
Trial Timeline
Apr 18, 2018 → Feb 27, 2031
NCT ID
NCT03383458About Nivolumab
Nivolumab is a phase 3 stage product being developed by Ono Pharmaceutical for Hepatocellular Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT03383458. Target conditions include Hepatocellular Carcinoma, Liver Cancer.
What happened to similar drugs?
5 of 20 similar drugs in Hepatocellular Carcinoma were approved
Approved (5) Terminated (2) Active (14)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03987815 | Phase 2 | UNKNOWN |
| NCT03383458 | Phase 3 | Active |
| NCT03090737 | Phase 2 | Completed |
| NCT02857426 | Phase 2 | Completed |
| NCT02743494 | Phase 3 | Completed |
| NCT02632409 | Phase 3 | Active |
| NCT02387996 | Phase 2 | Completed |
Competing Products
20 competing products in Hepatocellular Carcinoma